HLA-S and cancer: Remarkable significance of these studies lies in the formal demonstrations of the possibility to develop agents with very high affinity (recognitions of very low HLA expressing cancer cells), with very high specificity (mutant vs wt HLAs), shifting the emphasis of the novel approaches in cancer immunotherapy from the cell-based strategies to bifunctional antibodies.